Mandate

Vinge has advised Oncopeptides in connection with entering into renewed agreements regarding a loan facility of up to EUR 30 million from the European Investment Bank

The loan agreement with the European Investment Bank (EIB) grants Oncopeptides access to a renewed unsecured loan facility of up to EUR 30 million. The loan facility agreement is divided into three tranches, each with a maturity of five years, which will become available if the company, inter alia, satisfies certain milestones related to the ongoing commercialization of Pepaxti® in Europe and a potential relaunch of Pepaxto® in the US. In connection with the loan agreement, Oncopeptides has entered into a renewed warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.

Oncopeptides is a biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company´s lead product is approved on several markets for treatment of adult patients with multiple myeloma. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Louise Brorsson Salomon, Arvid Weimers and Kamyar Najmi (finance) as well as Dain Hård Nevonen and Linnéa Sellström (capital markets).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025